Preclinical studies of toxicity and anti-cholangiocarcinoma activity of the standardized capsule formulation of Atractylodes lancea (Thunb.) DC
Abstract Background Cholangiocarcinoma (CCA), the adenocarcinoma of the biliary duct, is commonly reported in Asia, with the highest incidence in northeastern Thailand. Chemotherapy of CCA has been limited by the lack of effective chemotherapeutic drugs. A series of previous in vitro and in vivo stu...
Main Authors: | Tullayakorn Plengsuriyakarn, Kanawut Kotawong, Juntra Karbwang, Kesara Na-Bangchang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-06-01
|
Series: | BMC Complementary Medicine and Therapies |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12906-023-03992-z |
Similar Items
-
Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction
by: Teerachat Saeheng, et al.
Published: (2024-11-01) -
Network Pharmacology and Experimental Validation to Investigate the Antidepressant Potential of <i>Atractylodes lancea</i> (Thunb.) DC.
by: Ly Thi Huong Nguyen, et al.
Published: (2022-11-01) -
Bioassay for total serum bioactivity of Atractylodes lancea
by: Kesara Na-Bangchang, et al.
Published: (2023-01-01) -
Atractylodes lancea (Thunb.) DC. [Asteraceae] rhizome-derived exosome-like nanoparticles suppress lipopolysaccharide-induced inflammation in murine microglial cells
by: Kei Kawada, et al.
Published: (2024-04-01) -
Geoherbalism Metabolomic Analysis of <i>Atractylodes lancea</i> (Thunb.) DC. by LC-Triple TOF-MS/MS and GC-MS
by: Hailong Qiu, et al.
Published: (2023-08-01)